Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950716 | 1.00 | ADRB3 (0.42) | ADRB3HTR6PPARGKEAP1NFE2L2 | |
| SCHEMBL2950718 | 1.00 | ADRB3 (0.42) | ADRB3HTR6PPARGKEAP1NFE2L2 | |
| Trifluoroacetic Acid SCHEMBL2948283 | 0.96 | ADRB3 (0.40) | ADRB3HTR6PPARGKEAP1NFE2L2 | |
| Trifluoroacetic Acid SCHEMBL2944135 | 0.96 | ADRB3 (0.40) | ADRB3HTR6PPARGKEAP1NFE2L2 | |
| Dimethylformamide SCHEMBL27739511 | 0.95 | ADRB3 (0.40) | ADRB3HTR6PPARGKEAP1NFE2L2 | |
| SCHEMBL13240095 | 0.94 | ADRB3 (0.44) | ADRB3HTR6NTSR1 | |
| SCHEMBL2950135 | 0.94 | ADRB3 (0.42) | ADRB3HTR6KEAP1NFE2L2PFKFB3 | |
| SCHEMBL2950139 | 0.94 | ADRB3 (0.42) | ADRB3HTR6KEAP1NFE2L2PFKFB3 | |
| SCHEMBL2950142 | 0.94 | ADRB3 (0.42) | ADRB3HTR6KEAP1NFE2L2PFKFB3 | |
| SCHEMBL2950628 | 0.94 | ADRB3 (0.38) | ADRB3HTR6PPARGKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754756-B2 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-13 | — | — | US | claimed |
| CN-101296903-A | Novel indole-containing beta agonists, method for the production thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | claimed |
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | claimed |
| US-7754756-B2 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| US-7754756-B2 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| US-7754756-B2 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| CN-101296903-A | Novel indole-containing beta agonists, method for the production thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007048841-A2 | NOVEL INDOLE-CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105906-A1 | Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885HTR6 172/4885PPARG 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.